Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
- Conditions
- Relapsed / Refractory MDSRelapsed / Refractory AML
- Interventions
- Drug: BYON4413
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT06359002
- Locations
- ๐ง๐ช
Het Ziekenhuisnetwerk Antwerpen, Antwerpen, Belgium
๐ง๐ชUZ Leuven, Leuven, Belgium
๐ณ๐ฑUniversitair Medisch Centrum Groningen, Groningen, Netherlands
First-in-human Dose Escalation and Expansion Study With the SIRPฮฑ-directed Monoclonal Antibody BYON4228
- Conditions
- Lymphoma
- Interventions
- Drug: BYON4228 + Rituximab
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT05737628
- Locations
- ๐ฎ๐น
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST, Ravenna, Italy
๐ฎ๐นASST Spedali Civili di Brescia, Brescia, Italy
๐ฎ๐นIstituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Italy
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
- Conditions
- Solid Tumor
- Interventions
- Drug: BYON3521
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 31
- Registration Number
- NCT05323045
- Locations
- ๐ฎ๐น
Istituto Europeo di Oncologia, Milan, Italy
๐ง๐ชInstitut Jules Bordet, Brussels, Belgium
๐ณ๐ฑRadboud, Nijmegen, Netherlands
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: BYON5667 & SYD985Drug: Placebo & SYD985
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT04983238
- Locations
- ๐ง๐ช
University Hospital Antwerp, Antwerp, Belgium
๐ง๐ชUZ Leuven, Leuven, Belgium
๐ช๐ธVall d' Hebron, Barcelona, Spain
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT04235101
- Locations
- ๐ง๐ช
University Hospital Antwerp, BE, Antwerp, Belgium
๐ณ๐ฑRadboud University Medical Center/ NL, Nijmegen, Netherlands
๐ฌ๐งThe Christie NHS Foundation Trust/ UK, Manchester, United Kingdom
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
- Conditions
- Endometrial Cancer
- Interventions
- Drug: SYD985
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 64
- Registration Number
- NCT04205630
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
๐ฐ๐ทSeverance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
- Conditions
- Solid Tumor
- Interventions
- Drug: SYD1875
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 31
- Registration Number
- NCT04202705
- Locations
- ๐ซ๐ท
Institut Bergoniรฉ, Bordeaux, France
๐ง๐ชInstitut Jules Bordet, Brussels, Belgium
๐ซ๐ทCentre Oscar Lambret, Lille, France
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: (vic-)trastuzumab duocarmazineDrug: Physician's choice
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 437
- Registration Number
- NCT03262935
- Locations
- ๐ง๐ช
CHU Liege, Liege, Belgium
๐ฌ๐งVelindre Cancer Centre VCC, Cardiff, United Kingdom
๐ฌ๐งThe Royal Marsden NHS Foundation Trust, London, United Kingdom
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
- Conditions
- Solid Tumors
- Interventions
- Drug: SYD985 (trastuzumab vc-seco-DUBA)
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 185
- Registration Number
- NCT02277717
- Locations
- ๐ช๐ธ
Institut Catala d'Oncologia, Barcelona, Spain
๐ณ๐ฑUMC, Rotterdam, Netherlands
๐ง๐ชInstitut Jules Bordet, Brussels, Belgium